Reference Tissue–Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The goal of this paper was to evaluate the in vivo kinetics of the novel tau-specific PET radioligand 18F-AV-1451 in cognitively healthy control (HC) and Alzheimer disease (AD) subjects, using reference region analyses. Methods:18F-AV-1451 PET imaging was performed on 43 subjects (5 young HCs, 23 older HCs, and 15 AD subjects). Data were collected from 0 to 150 min after injection, with a break from 100 to 120 min. T1-weighted MR images were segmented using FreeSurfer to create 14 bilateral regions of interest (ROIs). In all analyses, cerebellar gray matter was used as the reference region. Nondisplaceable binding potentials (BPNDs) were calculated using the simplified reference tissue model (SRTM) and SRTM2; the Logan graphical analysis distribution volume ratio (DVR) was calculated for 30–150 min (DVR30–150). These measurements were compared with each other and used as reference standards for defining an appropriate 20-min window for the SUV ratio (SUVR). Pearson correlations were used to compare the reference standards to 20-min SUVRs (start times varied from 30 to 130 min), for all values, for ROIs with low 18F-AV-1451 binding (lROIs, mean of BPND + 1 and DVR30–150 < 1.5), and for ROIs with high 18F-AV-1451 binding (hROIs, mean of BPND + 1 and DVR30–150 > 1.5). Results: SRTM2 BPND + 1 and DVR30–150 were in good agreement. Both were in agreement with SRTM BPND + 1 for lROIs but were greater than SRTM BPND + 1 for hROIs, resulting in a nonlinear relationship. hROI SUVRs increased from 80–100 to 120–140 min by 0.24 ± 0.15. The SUVR time interval resulting in the highest correlation and slope closest to 1 relative to the reference standards for all values was 120–140 min for hROIs, 60–80 min for lROIs, and 80–100 min for lROIs and hROIs. There was minimal difference between methods when statistical significance between ADs and HCs was calculated. Conclusion: Despite later time periods providing better agreement between reference standards and SUVRs for hROIs, a good compromise for studying lROIs and hROIs is SUVR80–100. The lack of SUVR plateau for hROIs highlights the importance of precise acquisition time for longitudinal assessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Primary age-related tauopathy (PART): a common pathology associated with human aging
Crary, J. F., Trojanowski, J. Q., Schneider, J. A., Abisambra, J. F., Abner, E. L., Alafuzoff, I., Arnold, S. E., Attems, J., Beach, T. G., Bigio, E. H., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1349-0 · Cited by 1,467 · cited 1×
“175273 Pathologic accumulation of the tau protein in the form of neurofibrillary tangles and paired helical filaments is common in normal aging and Alzheimer disease (AD) (1,2).”
BackgroundNeuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · cited 1×
“Because tau accumulation is not seen in these regions in AD brain (1,20), the faster clearance is thought to be associated with off-target binding.”
BackgroundTau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Marquié, M., Normandin, M. D., Vanderburg, C. R., Costantino, I. M., Bien, E. A., Rycyna, L. G., Klunk, W. E., Mathis, C. A., Ikonomovic, M. D., Debnath, M. L., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24517 · Cited by 615
[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605 · cited 1×
“Another series of tracers includes 18F-T807, also known as 18F-AV-1451 (11), and 18F-T808 (12).”
BackgroundTau imaging: early progress and future directions
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70252-2 · Cited by 501 · cited 2×
“Given such challenges, a validated tau tracer for AD must have numerous distinctive properties related to specificity, pharmacokinetics, and metabolism (3) and have minimal off-target binding.”
Background18F-THK5351: A Novel PET Radiotracer for Imaging Neurofibrillary Pathology in Alzheimer Disease
Harada, R., Okamura, N., Furumoto, S., Furukawa, K., Ishiki, A., Tomita, N., Tago, T., Hiraoka, K., Watanuki, S., Shidahara, M., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.164848 · Cited by 330 · cited 1×
“Tohoku University has developed several potential tau tracers, including 18F-THK523 (4–6), 18F-THK5117, 18F-THK5105 (7–9), and 18F-THK5351 (10).”
Background
Research works printed but not linked: 16
- 10.1007/s00259-012-2261-2 · DOI · Paper page
- 10.1186/alzrt240 · DOI · Paper page
- 10.1007/s00259-013-2681-7 · DOI · Paper page
- 10.2967/jnumed.112.117341 · DOI · Paper page
- 10.1093/brain/awu064 · DOI · Paper page
- 10.1007/s11910-014-0500-6 · DOI · Paper page
- 10.3233/JAD-130098 · DOI · Paper page
- 10.1006/nimg.1996.0066 · DOI · Paper page
- 10.1097/00004647-199609000-00008 · DOI · Paper page
- 10.1006/nimg.1997.0303 · DOI · Paper page
- 10.1097/01.WCB.0000033967.83623.34 · doi:10.1097/01.wcb.0000033967.83623.34 · Paper page
- Murtagh, 1984, A survey of recent advances in hierarchicial clustering algorithms, Comput J., 26, 354, 10.1093/comjnl/26.4.354 · DOI · Paper page
- 10.1109/TAC.1974.1100705 · DOI · Paper page
- Landaw, 1984, Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations, Am J Physiol., 246, R665
- Shcherbinin S Schwarz AJ Joshi A . Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer’s disease. J Nucl Med. May 5, 2016 [Epub ahead of print]. · DOI · Paper page
- 10.1038/jcbfm.2014.202 · DOI · Paper page
Cited by
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease
Bejanin, A., Schonhaut, D. R., La Joie, R., Kramer, J. H., Baker, S. L., Sosa, N., Ayakta, N., Cantwell, A., Janabi, M., Lauriola, M., et al. (2017) · Brain · doi:10.1093/brain/awx243 · Cited by 778
Self-citationTau PET imaging in neurodegenerative tauopathies—still a challenge
Leuzy, A., Chiotis, K., Lemoine, L., Gillberg, P.-G., Almkvist, O., Rodriguez-Vieitez, E., & Nordberg, A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0342-8 · Cited by 628
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
Maass, A., Landau, S., Baker, S. L., Horng, A., Lockhart, S. N., La Joie, R., Rabinovici, G. D., & Jagust, W. J. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.058 · Cited by 462
Self-citationLongitudinal tau PET in ageing and Alzheimer’s disease
Jack, C. R., Wiste, H. J., Schwarz, C. G., Lowe, V. J., Senjem, M. L., Vemuri, P., Weigand, S. D., Therneau, T. M., Knopman, D. S., Gunter, J. L., et al. (2018) · Brain · doi:10.1093/brain/awy059 · Cited by 452
“It is worthwhile noting that sample sizes were similar with TBM-SyN and tau PET in CI A + , indicating that change in tau PET SUVR (Baker et al., 2017) should be an effective outcome measure in trials of putative disease modifying agents.”
ResultEntorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging
Maass, A., Lockhart, S. N., Harrison, T. M., Bell, R. K., Mellinger, T., Swinnerton, K., Baker, S. L., Rabinovici, G. D., & Jagust, W. J. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.2028-17.2017 · Cited by 286
Self-citation
Metadata
- Authors
- Baker, S. L., Lockhart, S. N., Price, J. C., He, M., Huesman, R. H., Schonhaut, D., Faria, J., Rabinovici, G., & Jagust, W. J.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2016-09-01
- Volume
- 58
- Issue
- 2
- Pages
- 332-338
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2509137736
- Cited by
- 110
- References
- 8
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.